Zero cervical cancer deaths in vaccinated young women

A landmark study published in The Lancet (June 2026), conducted using England's national mortality data from 2001 to 2024, found that no cervical cancer deat...

What Happened

A landmark study published in The Lancet (June 2026), conducted using England's national mortality data from 2001 to 2024, found that no cervical cancer deaths were recorded among women aged 20–24 years over the period 2020–2024 — a cohort in which HPV vaccination coverage reached close to 90%.
Researchers from Queen Mary University of London estimate that the HPV vaccination programme has prevented approximately 200 cervical cancer deaths in England so far, with researchers projecting near-zero cervical cancer mortality risk before age 30 for women vaccinated at age 12–13.
A complementary study in Scotland reported zero detected cervical cancer cases in individuals who received the HPV vaccine at ages 12–13.
India launched its first nationwide HPV vaccination campaign in 2026, offering the vaccine free of charge to approximately 11.5 million adolescent girls — a programme directly informed by global evidence of this kind.
India accounts for approximately one-fifth of global cervical cancer cases and one-quarter of global cervical cancer deaths annually, making the scale of potential impact of a successful HPV drive among the largest in the world.

Static Topic Bridges

Human Papillomavirus (HPV) and Cervical Cancer: The Causal Link

Human Papillomavirus (HPV) is a group of over 200 related viruses transmitted primarily through skin-to-skin and sexual contact. Persistent infection with high-risk HPV types — especially HPV 16 and HPV 18 — is the direct cause of approximately 99.7% of cervical cancer cases. HPV 16 and 18 together account for roughly 70% of all cervical cancers globally. Other high-risk types (HPV 31, 33, 45, 52, 58) account for an additional ~20%. Low-risk HPV types (HPV 6, 11) cause genital warts but do not cause cancer. Cervical cancer develops slowly over 10–20 years from initial HPV infection, passing through precancerous stages (cervical intraepithelial neoplasia, CIN) detectable by Pap smear or HPV DNA testing — this lag explains why the vaccine prevents cancer deaths seen in the 30–50 age group, decades after adolescent vaccination.

HPV 16 and 18: responsible for ~70% of cervical cancers globally; targeted by all approved HPV vaccines
HPV transmission: primarily sexual contact; highly prevalent — most sexually active adults will acquire HPV at some point
Incubation-to-cancer timeline: 10–20 years from HPV infection to invasive cervical cancer
Cervical cancer is the 4th most common cancer in women globally; entirely preventable with vaccination + screening
Cervical cancer screening methods: conventional Pap smear (cytology), liquid-based cytology, HPV DNA testing (most sensitive)

Connection to this news: The Lancet and Scotland studies demonstrate vaccine effectiveness precisely because the vaccinated cohorts (who received the vaccine in 2008 in the UK) are now entering the age at which, without vaccination, precancerous and cancerous lesions would begin appearing — and none are.

HPV Vaccines: Cervarix, Gardasil, and Cervavac (India's Indigenous Vaccine)

Three main HPV vaccines are approved globally. Cervarix (GlaxoSmithKline) is a bivalent vaccine targeting HPV types 16 and 18 — the two highest-risk cancer-causing types. Gardasil (Merck/MSD) is a quadrivalent vaccine targeting HPV 6, 11, 16, and 18, protecting against both cancer-causing types and genital-wart-causing types; Gardasil-9 extends coverage to 9 HPV types. Cervavac — India's first indigenous HPV vaccine, developed and manufactured by the Serum Institute of India — is also quadrivalent (HPV 6, 11, 16, 18). Phase 2/3 trials published in The Lancet Oncology (2023) demonstrated that two doses of Cervavac in girls and boys aged 9–14 generated immune responses non-inferior to three doses of Gardasil in women aged 15–26. Cervavac's domestic production reduces cost significantly, enabling inclusion in India's Universal Immunisation Programme (UIP).

Cervarix (bivalent): targets HPV 16 and 18; developed by GSK
Gardasil (quadrivalent): targets HPV 6, 11, 16, 18; Gardasil-9 adds types 31, 33, 45, 52, 58 — developed by Merck
Cervavac (quadrivalent): targets HPV 6, 11, 16, 18; developed by Serum Institute of India; India's first indigenous HPV vaccine; commercial launch September 2023
Cervavac cost: significantly lower than imported vaccines (estimated ₹200–400 per dose vs. ₹3,000+ for Gardasil); enables affordable scale-up
WHO recommended schedule: 2 doses at 9–14 years (before sexual debut) for maximum efficacy; 3 doses if starting at 15+ years
UK HPV vaccination programme began: 2008 (girls); extended to boys: 2019 — this is the cohort covered by the Lancet 2026 study

Connection to this news: The Lancet England study was conducted in a population vaccinated with Cervarix (the UK programme's original vaccine); the near-zero mortality result provides the benchmark for what India's Cervavac-based programme — targeting a far larger and more cancer-burdened population — could achieve over the next two decades.

India's Cervical Cancer Burden and National Cancer Control Programme

India bears a disproportionate share of the global cervical cancer burden: approximately 1.23 lakh (123,000) new cases and over 77,000 deaths annually — representing approximately 20% of global cases and 25% of global deaths. Cervical cancer is the second most common cancer among Indian women (after breast cancer) and the leading cancer killer in women in many lower-income states. Contributing factors include low screening coverage (only ~30% of eligible women screened), limited awareness, and healthcare access barriers. The National Cancer Control Programme (NCCP), restructured under the National Programme for Non-Communicable Diseases (NP-NCD), has expanded cancer care infrastructure. The National Health Mission (NHM) has supported screening, and the Ayushman Bharat scheme covers cancer treatment. India's inclusion of the HPV vaccine in the Universal Immunisation Programme (UIP) in 2023 and the 2026 nationwide roll-out for girls aged 9–14 represent a paradigm shift from treatment to prevention.

India's annual cervical cancer incidence: ~1.23 lakh new cases; deaths: ~77,000 (approximately 21 deaths per hour)
Cervical cancer rank in Indian women: 2nd most common cancer overall; leading cancer cause of death in some states
HPV vaccine added to Universal Immunisation Programme (UIP): 2023 (India); national roll-out for ~11.5 million girls: 2026
Target age for HPV vaccination in India: 9–14 years (adolescent girls, pre-exposure)
Cervical cancer screening coverage in India: approximately 30% of eligible women — a key gap
National Cancer Control Programme (NCCP): programme under MoHFW; focuses on prevention, early detection, and treatment
Pradhan Mantri Jan Arogya Yojana (Ayushman Bharat): covers cancer treatment under its health insurance component

Connection to this news: The Lancet study provides robust evidence that vaccination at age 12–13 effectively eliminates cervical cancer mortality in the vaccinated cohort by age 30 — an outcome that India can now anticipate for the 11.5 million girls vaccinated in 2026, over the next 15–20 years.

Universal Immunisation Programme (UIP) and Vaccine Inclusion Process

India's Universal Immunisation Programme is one of the largest public health programmes in the world, providing free vaccines to approximately 26 million newborns and 30 million pregnant women annually through a government-funded network. The programme is funded and administered by the Ministry of Health and Family Welfare under the National Health Mission. New vaccines are added to the UIP based on recommendations from the National Technical Advisory Group on Immunisation (NTAGI) — India's apex vaccine policy body — which evaluates epidemiological burden, vaccine safety, efficacy data, and cost-effectiveness before recommending inclusion. The HPV vaccine was recommended by NTAGI and included in UIP in 2023, with the nationwide adolescent girl roll-out commencing in 2026 — a process that unfolded over several years of evidence gathering, domestic manufacturing development (Cervavac), and programme preparation.

UIP vaccines currently include: BCG, OPV, Hepatitis B, DPT, Hib, PCV, IPV, MR/MMR, Rotavirus, Typhoid Conjugate, HPV (added 2023)
National Technical Advisory Group on Immunisation (NTAGI): apex body recommending vaccine policy in India
UIP reach: ~26 million newborns + 30 million pregnant women annually (among world's largest immunisation programmes)
2026 HPV campaign target: ~11.5 million adolescent girls (class 6 school-based delivery model)
Cervavac's WHO prequalification: sought and advancing — would enable global supply beyond India

Connection to this news: India's HPV vaccination drive in 2026 directly draws on exactly the kind of real-world evidence generated by the Lancet study — demonstrating that a high-coverage adolescent vaccination programme, sustained over a decade, can eliminate cervical cancer deaths in the vaccinated generation.

Key Facts & Data

Lancet study (June 2026): zero cervical cancer deaths in women aged 20–24 in England (2020–2024); ~90% HPV vaccine coverage in cohort
Scotland finding: zero cervical cancer cases in anyone vaccinated at age 12–13
Estimated deaths prevented by UK HPV programme: ~200 (England alone)
India's annual cervical cancer burden: ~1.23 lakh new cases; ~77,000 deaths; ~20% of global cases; ~25% of global deaths
HPV types 16 and 18: cause ~70% of cervical cancers globally
Cervavac: India's first indigenous quadrivalent HPV vaccine; developed by Serum Institute of India; commercial launch September 2023
Cervavac targets: HPV 6, 11, 16, 18 (same as Gardasil)
2026 nationwide India HPV campaign: ~11.5 million adolescent girls
Vaccine recommended age: 9–14 years (2-dose schedule); 3 doses if starting at 15+
UIP inclusion of HPV vaccine: 2023; NTAGI recommended
UK HPV programme started: 2008; extended to boys: 2019